Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Cardiff Oncology, Inc. (NASDAQ: CRDF)
CRDF Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-61.70%
Analyst Rating:
BUY
Analyst Forecast (1yr):
172.50%
CRDF Stock Analysis
CRDF
PE Ratio:
CRDF
PEG Ratio:
Not Available
CRDF
Forward EPS Growth (12 month):
0.00%
CRDF
PS Ratio:
183.6
CRDF
PSG Ratio:
-4
CRDF
Forward Revenue Growth (12 month):
-45.60%
CRDF Articles
No data was found